Abstract

AbstractJust like the drugs themselves, their metabolites have to be evaluated to succeed in a drug development and approval process. It is therefore essential to be able to predict drug metabolism and to synthesise sufficient metabolite quantities for further pharmacological testing. This study evaluates the possibility of using in vitro biotransformations to solve both these challenges in the case of testosterone as a representative component for steroids. The application of cells of Pichia pastoris with expressed membrane‐associated human liver cytochrome P450 enzyme (P450) 3A4 in two cycles of a preparative‐scale bioreactor experiment enabled the isolation of the common metabolites 6β‐hydroxytestosterone and 6β‐hydroxyandrostenedione on a 100 mg scale. Side‐product formation caused by enzymes intrinsic to P. pastoris was reduced. In addition more polar testosterone metabolites formed by a P450 3A4‐catalysed bioconversion, than the known mono‐hydroxylated ones, are reported and 6‐dehydro‐15β‐hydroxytestosterone as well as the di‐hydroxylated steroids 6β,16β‐dihydroxytestosterone, 6β,17β‐dihydroxy‐4‐androstene‐3,16‐dione and 6β,12β‐dihydroxyandrostenedione were isolated and verified by NMR analysis. Their respective biological significance remains to be investigated. Whole‐cell P450 catalysts expressed in P. pastoris qualify as a tool for the preparative‐scale synthesis of human metabolites. Biotransformation processes in combination with standard chemical procedures allow the isolation and characterisation even of minor drug metabolite products.magnified image

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call